The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- VALUING AND ACCESSING MEDICINES
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- HEALTH DATA
VALUING AND ACCESSING MEDICINES
Value and Access
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
RESEARCH, DEVELOPMENT AND MANUFACTURING
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
WORKING IN PARTNERSHIP
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
INDUSTRY REPUTATION
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
INTERNATIONAL, TRADE AND IP
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
HEALTH DATA
Health data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
ABPI Conference 2024
The ABPI’s flagship annual conference took place on 25 April 2024 and focused on "Delivering the future for UK life sciences".
State of the Discovery Nation 2024 Report
The ABPI partnered with the Medicines Discovery Catapult and the UK BioIndustry Association on the State of the Discovery Nation 2024 report. It looks at the landscape for UK early-stage research, and highlights the impact of recent economic instability on companies in the life sciences sector.
ABPI Manifesto for Investment, Health and Growth
This manifesto sets out the ABPI’s vision for how the UK can overtake its global competitors. Implementing these proposals will create a virtuous cycle, where investment in medicines and research accelerates future waves of innovation and attracts an increased UK share of global R&D.
NHS Industry Case Studies Library
Partnerships between the NHS and the pharmaceutical industry benefit patients and the NHS. Visit the ABPI's library of case studies of successful partnerships.
Pharma Impact Map
ABPI has published an interactive Pharma Impact Map, demonstrating the value of the pharmaceutical industry in different regional areas of all the four nations of the UK, down to constituency level. Data is available on economic value, manufacturing sites, jobs, NHS/industry collaborations, and research.
Latest news
ABPI respond to proposals to change the Statutory Scheme
The Association of the British Pharmaceutical Industry (ABPI) has published an executive summary of its consultation response to the government's proposed changes to the Statutory Scheme for branded medicines.
Embracing innovation can improve care and ease NHS pressures
Creating a culture of innovation can improve care and tackle some of the pressures faced by healthcare professionals, according to a new joint report from NHS leaders, charity CEOs and the pharmaceutical industry.
GSK’s Bill Dawson appointed head of UK medicines manufacturing alliance
Bill Dawson, Head of Biologics and Devices Manufacturing at GSK, has been appointed the new Chair of the MMIP, a body representing the voice of medicines manufacturing in the UK.
ABPI response to the Budget
The Association of the British Pharmaceutical Industry (ABPI) has welcomed measures in Chancellor Jeremy Hunt’s Budget to unlock investment in medical research and medicines manufacturing, and improve NHS productivity.
Latest blogs and events
Familiarity and trust: Why it matters to industry reputation and what we can we do about it
Jill Pearcy, the ABPI's Director of reputation at the ABPI, talks about why familiarity and trust matters to the pharmaceutical industry.
mRNA technology: navigating preclinical research for rare diseases
Philip Cruz, Country Medical Director at Moderna UK talks about the potential of mRNA technology for rare diseases in a blog for Rare Disease Day 2024.
June’s story of sickle cell
June has sickle cell, a genetic blood disorder that affects the red blood cells. She is one of the 1 in 17 people with a rare disease in the UK.
NICE/DSU/ABPI Masterclass – Optimising NICE submissions in oncology
NICE and the ABPI invite you to the second event in the NICE/DSU/ABPI Masterclass Programme in 2024 - Optimising NICE submissions in oncology
Key content hubs
The COP28 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/b10ppsss/40-8bn-turnover.jpg)
![R and D Investment [2]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
![Gross Value Added (GVA) [4]](/media/fi4hkeqh/figures-gva-14bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.